CN103505500B - A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof - Google Patents
A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof Download PDFInfo
- Publication number
- CN103505500B CN103505500B CN201310300254.0A CN201310300254A CN103505500B CN 103505500 B CN103505500 B CN 103505500B CN 201310300254 A CN201310300254 A CN 201310300254A CN 103505500 B CN103505500 B CN 103505500B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- hepatitis
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a kind of Chinese medicine composition for the treatment of hepatitis B, be made up of the crude drug of following proportion by weight: Nidus Vespae 5 ~ 30 parts, Folium Isatidis 10 ~ 60 parts, Radix Arnebiae (Radix Lithospermi) 15 ~ 40 parts, Eupolyphaga Seu Steleophaga 5 ~ 30 parts, the Radix Astragali 5 ~ 30 parts, Scolopendra 1 ~ 8 part, Radix Ginseng Rubra 3 ~ 30 parts.The invention also discloses the preparation method of the Chinese medicine composition of above-mentioned treatment hepatitis B, method one: all crude drug beats powder, sterilizing, inspection, makes preparation; Method two: Radix Arnebiae (Radix Lithospermi), Folium Isatidis, Radix Ginseng Rubra and Radix Astragali ethanol extraction, extracting solution concentrating under reduced pressure, concentrated thick paste is for subsequent use; Medical material slag and all the other crude drug decoct with water extraction, extracting solution concentrating under reduced pressure, and thick paste and alcohol extraction thick paste merge, drying gets dry extract, dry cream and adjuvant are mixed thoroughly, makes pharmaceutically acceptable preparation, as tablet, capsule, pill, powder or granule etc. are applied to clinical.Traditional Chinese medicine composition formula of the present invention is novel, and technique is simple, stable and controllable for quality, safe and effective, stable curative effect, has significant effect to treatment hepatitis B.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof.
Background technology
Hepatitis B infection is worldwide popular, the epidemic strength of different regions HBV infection is widely different, according to worldwide Health Organization, the whole world about 2,000,000,000 people once infected HBV, wherein 3.5 hundred million people are chronic infection, about have 1,000,000 people to die from liver failure caused by HBV infection, liver cirrhosis and primary hepatocarcinoma (HCC) every year.
The survey showed that for the prevalence of hepatitis B virus that China carried out in 2006, China's 1 ~ 59 years old crowd's hepatitis B surface antigen carrying rate is 7.18%, the HBsAg carrying rate of less than 5 years old children is only 0.96%, calculate accordingly, the existing Patients with Chronic HBV Infection of China about 9,300 ten thousand people, wherein has symptom to need the activeness hepatitis B patient for the treatment of to be about more than 2,000 ten thousand.
Suppress HBV to greatest extent, alleviate hepatocyte inflammatory necrosis and hepatic fibrosis, delay and reduce the generation of Liver failure, liver cirrhosis, HCC and complication thereof, thus make the life better quality and prolongation time-to-live, this is the overall goal for the treatment of hepatitis B.The common method of current treatment hepatitis B has IFN α treatment, nucleoside (acid) class Drug therapy and Chinese medicine preparation medicine.The advantage of Chinese medicine preparation treatment is that Chinese medicine composition prescription selects prescription according to theory of Chinese medical science, reasonably combined according to the property of medicine, reaches and can take into account many-sided effect.At present, there is the Chinese medicinal composition preparation of numerous treatment hepatitis B, such as: publication number is in the application for a patent for invention of CN1857518, with Herba Artemisiae Scopariae, the Radix Paeoniae Alba, Radix Polygoni Multiflori Preparata, Fructus Lycii, Fructus Schisandrae Chinensis, Radix Glycyrrhizae Preparata for raw material, make the Chinese medicine preparation of Treatment chronic Hepatitis B, this patent application treats chronic viral hepatitis B with soft nourishing the liver ruling by law emphatically; Application number is in the application for a patent for invention of 200910223491.5, with Radix Notoginseng, Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri, Radix Et Rhizoma Rhei, Herba Hedyotidis Diffusae, Fel Serpentis, Borneolum Syntheticum, artificial Calculus Bovis, artificial Moschus, Radix Curcumae and Monas cuspurpureus Went for raw material, make the preparation for the treatment of hepatitis B, this patent application focuses on heat-clearing and toxic substances removing, blood stasis-eliminating and stagnation-dissipating; Application number is in the application for a patent for invention of 201110363635.4, makes preparation by a certain percentage with Fructus Schisandrae Chinensis, Radix Bupleuri, Mahonia fortunei (Lindl.) Fedde, Fructus Lycii, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae, the Radix Paeoniae Alba through technique, for prevention and therapy hepatitis.But it is open there are no the document consistent or close with the present patent application formula.
Summary of the invention
The object of the present invention is to provide a kind of evident in efficacy, Chinese medicine composition of being applicable to treating hepatitis B.
Another object of the present invention is to provide a kind of preparation technology simple, more effectively can retain the effective ingredient in raw material, be suitable for the preparation method of the Chinese medicine composition of the treatment hepatitis B of suitability for industrialized production.
A kind of Chinese medicine composition for the treatment of hepatitis B provided by the invention, is made up of the crude drug of following proportion by weight: Nidus Vespae 5 ~ 30 parts, Folium Isatidis 10 ~ 60 parts, Radix Arnebiae (Radix Lithospermi) 15 ~ 40 parts, Eupolyphaga Seu Steleophaga 5 ~ 30 parts, the Radix Astragali 5 ~ 30 parts, Scolopendra 1 ~ 8 part, Radix Ginseng Rubra 3 ~ 30 parts.
Preferably, the proportion by weight of each crude drug is: Nidus Vespae 10 ~ 25 parts, Folium Isatidis 20 ~ 50 parts, Radix Arnebiae (Radix Lithospermi) 20 ~ 35 parts, Eupolyphaga Seu Steleophaga 8 ~ 25 parts, the Radix Astragali 8 ~ 25 parts, Scolopendra 2 ~ 5 parts, Radix Ginseng Rubra 5 ~ 25 parts.
Preferred, the proportion by weight of each crude drug is: Nidus Vespae 15 ~ 20 parts, Folium Isatidis 30 ~ 40 parts, Radix Arnebiae (Radix Lithospermi) 25 ~ 30 parts, Eupolyphaga Seu Steleophaga 10 ~ 15 parts, the Radix Astragali 10 ~ 15 parts, Scolopendra 2 ~ 5 parts, Radix Ginseng Rubra 5 ~ 10 parts.
Hepatitis B of the present invention comprises B virus hepatitis B, hepatic fibrosis or liver cirrhosis.Hepatitis B reason is experienced the gas of epidemic disease heresy and arrives, but how does not have and send out a patient, or sense evil after the acute onset moon remaining and more person, again protracted course of disease after thoughts heresy, form chronic person.Gathering of heresy, its gas must be empty, and protracted course of disease after sense is evil, form chronic person, it is particularly evident that it is weakened body resistance.Damp and hot evil pent-up is the Basic disease cause pathogenesis of hepatitis B, the chronic viral hepatitis B course of disease with the passing of time, " prolonged illness must the stasis of blood ", " prolonged illness must be empty ", damp and hot cementing puzzled, every hyperamization clots absorbing is stagnant, healthy energy is more empty, so that sb.'s illness took a turn for the worse and protracted course of disease, if symptom management not in time, the change of liver cirrhosis can be given birth to.Though its course of disease stage of chronic viral hepatitis B and liver cirrhosis has different, its pathogenesis is identical, is deficiency in origin and excess in superficiality, and empty person is positive QI-insufficiency first, and The liver and the kidney have a common source for the two, and with the passing of time, easily cause Liver and kidney two empty, the easy transmitting into the spleen of three's hepatopathy, QI of the spleen and stomach is also empty for hepatopathy; Reality person first prolonged illness must the stasis of blood, and the two is that damp and hot heresy is not gone, thus we with Radix Ginseng Rubra strongly invigorating primordial QI, Folium Isatidis heat-clearing and toxic substances removing for monarch; Radix Astragali invigorating the spleen and replenishing QI, Radix Arnebiae (Radix Lithospermi) heat-clearing and toxic substances removing are ministerial drug; Eupolyphaga Seu Steleophaga removing blood stasis, Nidus Vespae damp eliminating counteracting toxic substances, pathogen usually intruding into collateral in protracted disease, non-search to pick with insects be difficult to make contributions, therefore with Scolopendra dredging collateral counteracting toxic substances, be adjuvant drug.Full side's treatment of arthritis and promoting collateral and channels, reinforcement and elimination in combination, liver spleen kidney is ruled together, and hit chronic hepatitis B and liver cirrhosis pathogenesis, plays righting counteracting toxic substances altogether, the effect of promoting blood circulation to remove obstruction in the collateral, is used for the treatment of chronic hepatitis B and liver cirrhosis virus replication and enlivens, and weakened body resistance not notably.
A kind of preparation method for the treatment of the Chinese medicine composition of hepatitis B provided by the invention, comprises following two kinds:
Preparation method one: get the Nidus Vespae of proportional quantity, Folium Isatidis, Radix Arnebiae (Radix Lithospermi), Eupolyphaga Seu Steleophaga, the Radix Astragali, Scolopendra and Radix Ginseng Rubra crude drug, be ground into micropowder, sterilizing, inspection, makes preparation.
Preparation method two: get the Radix Arnebiae (Radix Lithospermi) of proportional quantity, Folium Isatidis, Radix Ginseng Rubra and Astragalus membranaceus raw material medicinal 6-12 times amount 60 ~ 90% ethanol extraction, extracting solution concentrating under reduced pressure, concentrated thick paste is for subsequent use; The Nidus Vespae of medical material slag and proportional quantity, Scolopendra, Eupolyphaga Seu Steleophaga crude drug add 8-15 times amount water boiling and extraction, extracting solution concentrating under reduced pressure, and thick paste and alcohol extraction thick paste merge, and drying gets dry extract, and is mixed by dry cream with adjuvant, makes pharmaceutically acceptable preparation.
Pharmaceutically acceptable preparation of the present invention is tablet, capsule, pill, powder or granule.
Chinese medicine composition clinical practice of the present invention for many years, obtains good therapeutic effect.Verify preparation technology's gained sample of the present invention further by animal experiment, result shows that Chinese medicine composition of the present invention all has obvious anti-making to use to hepatitis B, Hepatic Fibrosis of Animal test.Result shows, Chinese medicine composition of the present invention is stable and controllable for quality, safe and effective, and stable curative effect has significant curative effect to hepatitis B.
Detailed description of the invention
The present invention is further illustrated below by detailed description of the invention; following examples are the concrete embodiment of the present invention; but embodiments of the present invention are not by the restriction of following embodiment; change, the modification done under other any does not deviate from spirit of the present invention and principle, substitute, combine, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Embodiment 1
Crude drug proportioning: Folium Isatidis 180g, Radix Arnebiae (Radix Lithospermi) 270g, Radix Ginseng Rubra 54g, Radix Astragali 90g, Eupolyphaga Seu Steleophaga 90g, Nidus Vespae 90g, Scolopendra 18g.
Preparation technology: all crude drug is ground into micropowder, sterilizing, inspection, adds 50g magnesium stearate, filled capsules, to obtain final product.
Embodiment 2
Crude drug proportioning: Folium Isatidis 120g, Radix Arnebiae (Radix Lithospermi) 80g, Radix Ginseng Rubra 60g, Radix Astragali 60g, Eupolyphaga Seu Steleophaga 60g, Nidus Vespae 60g, Scolopendra 16g.
Preparation technology: be all ground into micropowder after crude drug moist heat sterilization, add the long and slender plain 60g of crystallite, lactose 60g all closes, and granulates with starch slurry, dry, adds 50g silicon dioxide, tabletting, to obtain final product.
Embodiment 3
Crude drug proportioning: Folium Isatidis 300g, Radix Arnebiae (Radix Lithospermi) 75g, Radix Ginseng Rubra 150g, Radix Astragali 150g, Eupolyphaga Seu Steleophaga 25g, Nidus Vespae 200g, Scolopendra 40g.
Preparation technology: get the Folium Isatidis of proportional quantity, Radix Arnebiae (Radix Lithospermi), Radix Ginseng Rubra, the Radix Astragali add 8 times of 80% ethanol heating extraction 2 times, extracting solution concentrating under reduced pressure becomes thick paste for subsequent use; Alcohol extraction medicinal residues and Nidus Vespae, Eupolyphaga Seu Steleophaga, Scolopendra add 10 times amount water boiling and extraction 2 times, extracting solution concentrating under reduced pressure become after thick paste with alcohol extraction thick paste, vacuum drying gets dry extract 248g.Dried cream powder is broken, and add 80g microcrystalline Cellulose and granulate, mix with 25g carboxymethyl starch sodium, 10g silicon dioxide after granulate, tabletting, to obtain final product.
Embodiment 4
Crude drug proportioning: Folium Isatidis 100g, Radix Arnebiae (Radix Lithospermi) 150g, Radix Ginseng Rubra 30g, Radix Astragali 300g, Eupolyphaga Seu Steleophaga 300g, Nidus Vespae 50g, Scolopendra 80g.
Preparation technology: get the Folium Isatidis of proportional quantity, Radix Arnebiae (Radix Lithospermi), Radix Ginseng Rubra, the Radix Astragali add 10 times of 60% ethanol heating extraction 2 times, extracting solution concentrating under reduced pressure becomes thick paste for subsequent use; Alcohol extraction medicinal residues and Nidus Vespae, Eupolyphaga Seu Steleophaga, Scolopendra add 15 times amount water boiling and extraction 1 time, extracting solution concentrating under reduced pressure become after thick paste with alcohol extraction thick paste, vacuum drying gets dry extract 153g.Dried cream powder is broken, add pre-paying of 80g starch and 16gPVP mixing, with 50% ethanol soft material, mould method for making and make pill, dry, to obtain final product.
Embodiment 5
Crude drug proportioning: Folium Isatidis 100g, Radix Arnebiae (Radix Lithospermi) 400g, Radix Ginseng Rubra 300g, Radix Astragali 50g, Eupolyphaga Seu Steleophaga 300g, Nidus Vespae 300g, Scolopendra 10g.
Get medicinal 12 times amount 90% ethanol extractions of the Radix Arnebiae (Radix Lithospermi) of proportional quantity, Folium Isatidis, Radix Ginseng Rubra and Astragalus membranaceus raw material, extracting solution concentrating under reduced pressure, concentrated thick paste is for subsequent use; The Nidus Vespae of medical material slag and proportional quantity, Scolopendra, Eupolyphaga Seu Steleophaga crude drug add 8 times amount water boiling and extraction, extracting solution concentrating under reduced pressure, and thick paste and alcohol extraction thick paste merge, and drying gets dry extract, and is mixed by dry cream with 55g magnesium stearate, filled capsules and get final product.
Embodiment 6
Crude drug proportioning: Folium Isatidis 350g, Radix Arnebiae (Radix Lithospermi) 270g, Radix Ginseng Rubra 80g, Radix Astragali 120g, Eupolyphaga Seu Steleophaga 120g, Nidus Vespae 100g, Scolopendra 30g.
Get medicinal 12 times amount 80% ethanol extractions of the Radix Arnebiae (Radix Lithospermi) of proportional quantity, Folium Isatidis, Radix Ginseng Rubra and Astragalus membranaceus raw material, extracting solution concentrating under reduced pressure, concentrated thick paste is for subsequent use; The Nidus Vespae of medical material slag and proportional quantity, Scolopendra, Eupolyphaga Seu Steleophaga crude drug add 12 times amount water boiling and extraction, extracting solution concentrating under reduced pressure, and thick paste and alcohol extraction thick paste merge, drying gets dry extract, and dry cream and 50g cane sugar powder is mixed, additional magnesium stearate 45g mixing, make granule, dry, to obtain final product.
Pharmacodynamics test is studied
Chinese medicine composition of the present invention has following effect:
(1) hepatitis virus resisting effect raises the clear middle DHBV-DNA of the Sanguis Anas domestica of infected duck hepatitis B virus (DHBV) good inhibitory action.
(2) effect of anti hepatic fibrosis can reduce serum alt, AST, Liver hydroxyproline content to carbon tetrachloride chronic hepatic injury, improve TP and albumin A LB content (P<0.05) in serum, pathological examination results shows there is obvious repair to liver injury;
(3) rising of function for protecting liver and reducing enzyme activity to D-galactosamine (D-GalN) induced mice Serum alanine aminotransferase (ALT), Aspartic Acid aminotransferase (AST) also has stronger inhibitory action, histological examination, to respectively by CCl
4, D-GalN cause animal liver damage, there is certain protective effect.
Beneficial effect of the present invention is set forth further below by way of pharmacodynamics test.
1, experiment material:
1.1 test medicine: the sample that embodiment 3 is obtained
1.2 positive control drugs: bifendate drop pill, Beijing XieHe medicine Factory; Lamivudine, Glaxowellcome Products, 100mg/ sheet.
1.3 experimental animals: SD rat, kunming mice: SPF level, purchased from Zhongshan University's Experimental Animal Center.L age in days Guangzhou sheldrake duckling (male and female regardless of), purchased from Tang Xi hatchery, Guangzhou.
1.4 reagent: Aspartic Acid aminotransferase (AST) test kit; ALT (ALT) test kit; Total protein (TP) test kit; Albumin (ALB) test kit;
1.5 DHBs (DHBV-DNA) strong positive serum, picks up from Shanghai and infects hepatitis B virus sheldrake ,-70 DEG C of preservations.
1.6 instruments: automatic clinical chemistry analyzer; Dual-beam ultraviolet-uisible spectrophotometer;
2 experimental techniques and result
2.1 in duck body on the impact of DHB:
Get 1 age in days Guangzhou sheldrake, clear through the positive Sanguis Anas domestica of lower limb shin intravenous injection Shanghai sheldrake DHBV-DNA, every 0.3ml, infects and gets blood, separation of serum in latter 7 days, detects DHBV-DNA content in serum.Duck after DHBV is positive after testing, is divided into 5 groups, virus control group, lamivudine group (50mg/kg), Chinese medicine composition three dosage groups by duckling serum at random, often organizes 8.Gastric infusion, 1.5ml/, every day 2 times.Matched group gives same volume normal saline, successive administration 14 days.Respectively with Drug therapy after 7 days (T7), after 14 days (T14) and drug withdrawal 3 days (P3) from duck shin venous blood sampling, separation of serum, by nick translation test kit description method, with 32P labelling DHBVDNA probe, and make the clear dot blot hybridization of Sanguis Anas domestica, autoradiography diaphragm speckle, microplate reader measures OD value (optical filter is 490nm), calculate serum DHBV-DNA optical density, using hybridization spot OD value as specimen DHBV-DNA level value.The results are shown in Table 1.
Table 1 is on the impact of the horizontal suppression ratio of the clear DHBV-DNA of Sanguis Anas domestica
Note: compare with matched group
*p<0.05; #P<0.01
Table 2 in duck body on the impact (n=7-8) of DHB DHBV-DNA
Note: compare with matched group
*p<0.05; #P<0.01
(after administration, different time (T5, T10, P3) OD value compares (paired t-test) with (T0) OD value before organizing administration.
Above experimental result shows: Chinese medicine composition of the present invention has good therapeutical effect to duck hepatitis B virus infection duck.
The therapeutical effect of 2.2 pairs of carbon tetrachloride chronic hepatic injuries
Select healthy SD rat, random taking-up 15 is blank group.All the other rat skin lower injection 40% carbon tetrachloride oil solutions, injection 2 times in 1 week, continuous 15 times.Injection CCl
4after 50d, rat is divided into 6 groups at random by body weight, (grouping, dosage are in table 1), gastric infusion, every day 1 time, continuous 30d.Blank group and model group are to same volume 0.5%CMC-Na solution.1h after last administration, gets blood, measures serum alt, AST, TP, ALB content.Separately get the liver 0.5g at the same position of hepatomegaly leaf, preparation liver homogenate, measure hydroxyproline content, the hepatic tissue separately getting hepatomegaly leaf same area does routine pathology histological examination.
Table 3 is on the impact (x ± s, n=8-10) of carbon tetrachloride chronic hepatic injury rat blood serum biochemical indicator
Note: compare with model group
*p<0.05; #P<0.01
Table 4 is on the impact (n=8-10) of rat carbon tetrachloride hepatic injury
Liver Damage in Rats pathological grading:
" 0 " level normal liver tissue: liver rope marshalling, sinus hepaticus is obvious, and cell size is normal, and endochylema is even, and kernel, nuclear membrane are clear.
"+" level is slight hepatic cell degeneration, and liver rope is substantially neat, and sinus hepaticus is visible, and hepatocyte is slightly large.Pathological changes is below 1/3.
" ++ " level is the degeneration of hepatocyte moderate, and based on Hepatocellular ballooning, liver rope arrangement disorder, pathological changes is below 1/2.
" +++ " level is the degeneration of hepatocyte severe, and based on Hepatocellular ballooning, lobules of liver structure disappears, and liver rope arrangement disorder, the visible spotty necrosis in community, pathological changes is more than 2/3.
Result shows, Chinese medicine composition of the present invention can reduce serum alt, AST, Liver hydroxyproline content to rat chronic hepatic injury caused by carbon tetrachloride, improve TP and albumin A LB content (P<0.05) in serum, pathological examination results shows there is obvious repair to liver injury.
The protective effect of 2.3 pairs of D-galactosamine induced mice acute liver damages
Get KM healthy mice, be divided at random 6 groups (grouping, dosage are in tables 3) by sex, body weight.Gastric infusion, daily 1 time, successive administration 7d, blank group and model group are to same volume 0.5%CMC-Na solution.6d after administration, except blank group, all the other respectively organize mice equal lumbar injection D-galactosamine 0.8gkg
-1.Last administration after 16h, and after administration 30min, mice vena ophthalmica clump gets blood, separation of serum, measures serum alt and AST content.And get liver and do pathological examination.
Table 5 pair D-galactosamine causes the protective effect (x ± s) of acute liver
Note: compare with model group
*p<0.05; #P<0.01
Table 6 causes the impact (n=10) of mouse liver injury to D-galactosamine
Mice D-galactosamine acute liver damage pathological tissues histological grading standard.
" 0 " level liver rope marshalling, sinus hepaticus is obvious, and cell size is normal, and endochylema is even, and kernel, nuclear membrane are clear.
"+" level liver rope is substantially neat, and sinus hepaticus is visible, and hepatocyte is slightly large.
" ++ " level liver rope arrangement disorder, swelling of liver cell, sinus hepaticus is not clearly.
" +++ " level lobules of liver is imperfect, liver rope arrangement disorder, hepatocyte enlargement, and sinus hepaticus can not be seen, the visible spotty necrosis in community.
Result shows; Chinese medicine composition of the present invention has certain protective effect to D-galactosamine induced mice acute liver damage; serum alt, AST value significantly reduce (P<0.05), and pathological examination results shows that high low dosage is to all visible significantly repair of liver injury.
Clinical practice embodiment
Patient Lee, man, 40 years old, within 2010, December was gone to a doctor on the 24th.Chronic hepatitis b disease history 8 years, because of metal fatigue, loss of appetite 12 days, eye is gone to a doctor for yellow 7 days.Sick just dizzy unable, anorexia, feel sick and detest oil, upper abdomen is vexed swollen, and continuing, it is yellow as strong tea shape then to urinate color depth, nearest 7 days discovery yellow skin and eyes, tongue in bitter taste, loss of appetite.Have a medical check-up, sclera and the obvious xanthochromia of skin, Shang Gan circle plays white right side the 6th intercostal, lower bound under right rib under 10cm, xiphoid-process 3.0cm can touch, medium hardness, obviously kowtows tenderness, and spleen does not touch.Chemical examination: alanine aminotransferase 2160U/L, AST 1084U/L, total bilirubin 156.89 μm of ol/L, bilirubin direct lOO μm ol/L.The left string of arteries and veins and right slow, light red tongue yellow and greasy fur, the bitter and not tending to drink water of xerostomia, yellowish urine is red.Patient is reluctant to be in hospital, therefore gives out-patient treatment, advises further consultation on time to take a good rest.Give the sample after 3 days taking embodiment 6, diet increases, and within 2 weeks, tongue is clean afterwards.Following the service is after 2 weeks, and total bilirubin drops to 71.89 μm of ol/L, and alanine aminotransferase is down to 284U/L, and door winter acid aminotransferase is down to 268U/L.After continuing to take 1 month, alanine aminotransferase is down to normal range.
Patient tight certain, man, 43 years old.Suffer from more than 10 years of hepatitis B, within nearly 5 years, occur abnormal liver function whenever spring (2 to May), ALT, between 333.6 ~ 4117.49U/L, goes to a doctor on April 18th, 2012.Disease is seen: body order yellowish urine, dull pain in liver, and poor appetite detests oil, feels sick weak, gastral cavity painful abdominal mass abdominal distention, light red tongue, yellow and greasy fur, moderate pulse.Check: alanine aminotransferase is down to 1077U/L, door winter acid aminotransferase is down to 849U/L, total bilirubin 200.21 μm of ol/L, bilirubin direct 152 μm of ol/L.Give the sample treatment taking embodiment 6, first quarter moon of taking medicine, jaundice is most, and liver function is close to normal.More than the following the service l month, each index all recovers normal, advises and takes 1 month consolidate curative effect again.Follow up a case by regular visits to and have no recurrence in 2 years.
Claims (6)
1. treat the Chinese medicine composition of hepatitis B for one kind, it is characterized in that, be made up of the crude drug of following proportion by weight: Nidus Vespae 5 ~ 30 parts, Folium Isatidis 10 ~ 60 parts, Radix Arnebiae (Radix Lithospermi) 15 ~ 40 parts, Eupolyphaga Seu Steleophaga 5 ~ 30 parts, the Radix Astragali 5 ~ 30 parts, Scolopendra 1 ~ 8 part, Radix Ginseng Rubra 3 ~ 30 parts.
2. a kind of Chinese medicine composition for the treatment of hepatitis B according to claim 1, it is characterized in that, the proportion by weight of each crude drug is: Nidus Vespae 10 ~ 25 parts, Folium Isatidis 20 ~ 50 parts, Radix Arnebiae (Radix Lithospermi) 20 ~ 35 parts, Eupolyphaga Seu Steleophaga 8 ~ 25 parts, the Radix Astragali 8 ~ 25 parts, Scolopendra 2 ~ 5 parts, Radix Ginseng Rubra 5 ~ 25 parts.
3. a kind of Chinese medicine composition for the treatment of hepatitis B according to claim 1, it is characterized in that, the proportion by weight of each crude drug is: Nidus Vespae 15 ~ 20 parts, Folium Isatidis 30 ~ 40 parts, Radix Arnebiae (Radix Lithospermi) 25 ~ 30 parts, Eupolyphaga Seu Steleophaga 10 ~ 15 parts, the Radix Astragali 10 ~ 15 parts, Scolopendra 2 ~ 5 parts, Radix Ginseng Rubra 5 ~ 10 parts.
4. a preparation method for the Chinese medicine composition for the treatment of hepatitis B according to claim 1, is characterized in that, gets the Nidus Vespae of proportional quantity, Folium Isatidis, Radix Arnebiae (Radix Lithospermi), Eupolyphaga Seu Steleophaga, the Radix Astragali, Scolopendra and Radix Ginseng Rubra crude drug, be ground into micropowder, sterilizing, inspection, makes preparation.
5. the preparation method of the Chinese medicine composition of a treatment hepatitis B according to claim 1, it is characterized in that, get the Radix Arnebiae (Radix Lithospermi) of proportional quantity, Folium Isatidis, Radix Ginseng Rubra and Astragalus membranaceus raw material medicinal 6-12 times amount 60 ~ 90% ethanol extraction, extracting solution concentrating under reduced pressure, concentrated thick paste is for subsequent use; The Nidus Vespae of medical material slag and proportional quantity, Scolopendra, Eupolyphaga Seu Steleophaga crude drug add 8-15 times amount water boiling and extraction, extracting solution concentrating under reduced pressure, and thick paste and alcohol extraction thick paste merge, and drying gets dry extract, and is mixed by dry cream with adjuvant, makes pharmaceutically acceptable preparation.
6. a kind of preparation method for the treatment of the Chinese medicine composition of hepatitis B according to claim 4 or 5, is characterized in that, described preparation is tablet, capsule, pill, powder or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310300254.0A CN103505500B (en) | 2013-07-17 | 2013-07-17 | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310300254.0A CN103505500B (en) | 2013-07-17 | 2013-07-17 | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103505500A CN103505500A (en) | 2014-01-15 |
| CN103505500B true CN103505500B (en) | 2015-09-09 |
Family
ID=49889272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310300254.0A Expired - Fee Related CN103505500B (en) | 2013-07-17 | 2013-07-17 | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103505500B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105561110A (en) * | 2016-03-03 | 2016-05-11 | 刘操 | Traditional Chinese medicine composition for curing hepatitis B as well as preparing method and application of traditional Chinese medicine composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100556446C (en) * | 2007-04-19 | 2009-11-04 | 韩曙光 | The Chinese medicine of treatment hepatocarcinoma |
| CN103007226A (en) * | 2012-12-24 | 2013-04-03 | 广西东兴市创新特色医药科技发展有限公司 | Drug for treating hepatocirrhosis ascites, and preparation method thereof |
-
2013
- 2013-07-17 CN CN201310300254.0A patent/CN103505500B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103505500A (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940785B (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN104043050A (en) | Traditional Chinese medicine composition for treating cholecystitis | |
| CN102178788B (en) | Chinese medicinal composition for reducing transaminase and jaundice and preparation method thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof | |
| CN105267559A (en) | Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN101658636B (en) | Chinese medical composition for treating coronary heart disease | |
| CN102949659A (en) | Traditional Chinese medicine composition for treating hepatitis B | |
| CN103110756B (en) | Traditional Chinese medicine composition for treating renal hematuria | |
| CN102114211B (en) | Chinese herbal medicine for treating hepatopathy | |
| CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN103830464A (en) | Traditional Chinese medicine composition for treating apoplexy and preparation method thereof | |
| CN102846965A (en) | Traditional Chinese medicine preparation capable of resisting HIV and improving immunity and preparation method of traditional Chinese medicine | |
| CN102488851A (en) | Drug for treating recurrent genital herpes and preparation method thereof | |
| CN101015671B (en) | Chinese patent drug for treating cirrhosis | |
| CN106109731A (en) | A kind of Chinese medicine composition treating chronic hepatopathy and preparation method thereof | |
| CN105327295A (en) | Capsules for treating hepatitis and preparing method thereof | |
| CN104587017A (en) | Pharmaceutical composition for clearing heat and relaxing bowels, promoting qi and activating blood circulation as well as preparation method and application of pharmaceutical composition | |
| CN104491316A (en) | Traditional Chinese medicine preparation for treating middle-warmer energy insufficiency type prostate hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150909 Termination date: 20180717 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |